Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158.

Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing Haemophilia Care in Resource-Limited Countries: Current Challenges and Future Prospects. J Blood Med. 2023;14:141–6.

Article  PubMed  PubMed Central  Google Scholar 

Sidharthan N, Sudevan R. Low Dose Prophylaxis in Hemophilia Care. Indian J Hematol Blood Trans. 2020;36(1):16–25.

Article  Google Scholar 

Kwak H, Lee S, Jo S, Kwon YE, Kang H, Choi G, et al. MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. Res Pract Thromb Haemost. 2020;4(8):1301–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia. 2023;29(6):1419–29.

Article  CAS  PubMed  Google Scholar 

Seth T, Garg K, Mandal PK, Datta A, Verma S, Hanagavadi S, et al. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India. Hematology. 2023;28(1):2277497.

Article  PubMed  Google Scholar 

Brekkan A, Degerman J, Jönsson S. Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. Haemophilia. 2019;25(3):408–15.

Article  CAS  PubMed  Google Scholar 

Ay C, Kovacevic KD, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas C, et al. The von Willebrand Factor-Binding Aptamer Rondaptivon Pegol as a Treatment for Severe and Nonsevere Hemophilia A. Blood. 2023;141(10):1147–58.

Article  CAS  PubMed  Google Scholar 

Kovacevic KD, Buchtele N, Schoergenhofer C, Derhaschnig U, Gelbenegger G, Brostjan C, et al. The Aptamer BT200 Effectively Inhibits von Willebrand Factor (VWF) Dependent Platelet Function After Stimulated VWF Release by Desmopressin or Endotoxin. Sci Rep. 2020;10(1):11180.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kovacevic KD, Grafeneder J, Schörgenhofer C, Gelbenegger G, Gager G, Firbas C, et al. The von Willebrand Factor A-1 Domain Binding Aptamer BT200 Elevates Plasma Levels of von Willebrand Factor and Factor VIII: A First-In-Human Trial. Haematologica. 2022;107(9):2121–32.

Article  CAS  PubMed  Google Scholar 

Zhu S, Gilbert JC, Liang Z, Kang D, Li M, Tarantino PM, et al. Potent and Rapid Reversal of the von Willebrand Factor Inhibitor Aptamer BT200. J Thromb Haemost. 2020;18(7):1695–704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turecek PL, Johnsen JM, Pipe SW, O’Donnell JS. the i Psg. Biological Mechanisms Underlying Inter-Individual Variation in Factor VIII Clearance in Haemophilia. Haemophilia. 2020;26(4):575–83.

Article  PubMed  PubMed Central  Google Scholar 

Choin A, Aguila S, Fazavana J, Byrne C, Ward S, O’Sullivan J, et al., editors. Aptamer BT200 prolongs VWF half-life by blocking interaction with macrophage scavenger receptor LRP1. International Society on Thrombosis and Haemostasis; 2023; Montréal, Canada.

Grifols Biologicals Inc. Package Insert - Alphanate2018. Available from: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/alphanate. Accessed 21 Apr 2023.

Honda S, Shimahara Y, Chikasawa Y, Ogino H. Hemostatic protocol and risk-reduction surgery for treating coronary artery disease with aortic stenosis in a patient with combined coagulation factor VIII and XI deficiency: a case report. Eur Heart J Case Rep. 2023;7(5):ytad219.

Article  PubMed  PubMed Central  Google Scholar 

Beal SL, Sheiner LB, Boeckman AJ, Bauer RJ. NONMEM 7.4 Users Guide1989–2018. Available from: https://nonmem.iconplc.com/nonmem743/guides. Accessed 22 May 2023.

Bauer RJ. NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):525–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

R Core Team. R: A Language and Environment for Statistical Computing2023. Available from: https://www.R-project.org/. Accessed 20 Mar 2023.

Beal SL. Ways to Fit a PK Model with Some Data Below the Quantification Limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.

Article  CAS  PubMed  Google Scholar 

McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. Development and Evaluation of a Generic Population Pharmacokinetic Model for Standard Half-Life Factor VIII for Use in Dose Individualization. J Pharmacokinet Pharmacodyn. 2019;46(5):411–26.

Article  CAS  PubMed  Google Scholar 

Bukkems LH, Heijdra JM, de Jager NCB, Hazendonk HCAM, Fijnvandraat K, Meijer K, et al. Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. Blood Adv. 2021;5(5):1513–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125(13):2029–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, et al. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clin Pharmacokinet. 2020;59(2):245–56.

Article  CAS  PubMed  Google Scholar 

Dayneka NL, Garg V, Jusko WJ. Comparison of Four Basic Models of Indirect Pharmacodynamic Responses. J Pharmacokinet Biopharm. 1993;21(4):457–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee M, Jeong Y-S, Kim M-S, An K-M, Chung S-J. Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics. Pharmaceutics [Internet]. 2022; 14(6).

Keating GM, Dhillon S. Octocog Alfa (Advate®): A Guide to Its Use in Hemophilia A. BioDrugs. 2012;26(4):269–73.

Article  CAS  PubMed  Google Scholar 

Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–58.

Article  CAS  PubMed  Google Scholar 

Lee W, Kim M-S, Kim J, Aoki Y, Sugiyama Y. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic–TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions. Drug Metab Dispos. 2023;51(9):1145.

Article  CAS  PubMed  Google Scholar 

West GB, Brown JH, Enquist BJ. A General Model for the Origin of Allometric Scaling Laws in Biology. Science. 1997;276(5309):122–6.

Article  CAS  PubMed  Google Scholar 

McLeay SC, Morrish GA, Kirkpatrick CMJ, Green B. The Relationship between Drug Clearance and Body Size. Clin Pharmacokinet. 2012;51(5):319–30.

Article  CAS  PubMed  Google Scholar 

Chelle P, Yeung CHT, Bonanad S, Morales Muñoz JC, Ozelo MC, MegíasVericat JE, et al. Routine Clinical Care Data for Population Pharmacokinetic Modeling: The Case for Fanhdi/Alphanate in Hemophilia a Patients. J Pharmacokinet Pharmacodyn. 2019;46(5):427–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of Fat-Free Mass in Children. Clin Pharmacokinet. 2015;54(11):1169–78.

Article  CAS  PubMed  Google Scholar 

Sinha J, Duffull SB, Al-Sallami HS. A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass. Clin Pharmacokinet. 2018;57(7):781–95.

Article  PubMed  Google Scholar 

Michaela M, Sebastian S, Bernd L, Lars K, Joerg L. Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling. Drug Metab Dispos. 2012;40(5):892.

Article  Google Scholar 

Jiménez-Yuste V, Auerswald G, Benson G, Lambert T, Morfini M, Remor E, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12(3):314–9.